Shares of Travere Therapeutics, Inc. (TVTX) plummeted nearly 8% on Thursday, November 8th, after the biopharmaceutical company announced the pricing of a public offering of common stock that could dilute existing shareholders.
On Wednesday evening, November 7th, Travere Therapeutics revealed that it had priced an underwritten public offering of approximately 7.81 million shares of its common stock at $16 per share. The offering is expected to raise gross proceeds of $125 million for the company.
The news of the share issuance was met with a significant sell-off, as investors anticipated a dilutive impact on the company's outstanding shares. Travere Therapeutics' stock opened at $17.25 on November 8th but quickly shed nearly 8% of its value, closing the trading session at $15.88.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。